KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Other Non Operating Income (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Other Non Operating Income for 13 consecutive years, with -$296000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non Operating Income rose 79.97% to -$296000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 226.69% increase, with the full-year FY2025 number at $1.3 million, up 226.69% from a year prior.
  • Other Non Operating Income was -$296000.0 for Q4 2025 at Xenon Pharmaceuticals, down from -$89000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $1.9 million in Q4 2021 to a low of -$2.4 million in Q3 2022.
  • A 5-year average of $31250.0 and a median of $76000.0 in 2021 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: crashed 1760.16% in 2022, then skyrocketed 16880.0% in 2025.
  • Xenon Pharmaceuticals' Other Non Operating Income stood at $1.9 million in 2021, then tumbled by 68.13% to $602000.0 in 2022, then tumbled by 114.95% to -$90000.0 in 2023, then plummeted by 1542.22% to -$1.5 million in 2024, then soared by 79.97% to -$296000.0 in 2025.
  • Per Business Quant, the three most recent readings for XENE's Other Non Operating Income are -$296000.0 (Q4 2025), -$89000.0 (Q3 2025), and $1.7 million (Q2 2025).